Summary
This 8-K filing details the results of Medtronic plc's 2019 Annual General Meeting of Shareholders, held on December 6, 2019. The meeting covered routine corporate governance matters, including the election of directors, ratification of auditors, executive compensation, and authorizations for share issuance and repurchases. Investor sentiment was overwhelmingly positive across all proposals, indicating strong shareholder confidence in the company's leadership and strategic direction. The overwhelming approval rates for director elections, auditor ratification, executive compensation, and various board authorities underscore a stable and well-supported governance framework at Medtronic.
Key Highlights
- 1All twelve nominated directors were overwhelmingly elected to the Board of Directors, with most receiving over 95% of the votes cast.
- 2PricewaterhouseCoopers LLP was ratified as the independent auditor for fiscal year 2020 with strong shareholder approval (95.7%).
- 3Shareholder approval for the compensation of named executive officers was high, with over 94.7% voting in favor on a non-binding advisory basis.
- 4Shareholders renewed the Board's authority to issue shares with nearly 99% approval.
- 5The Board's authority to opt out of pre-emption rights was renewed with over 99.2% approval.
- 6Authorization for the company and its subsidiaries to conduct overseas market purchases of Medtronic ordinary shares was approved with over 99.2% of the vote.
Frequently Asked Questions
This 8-K filing was made to report the final voting results from Medtronic plc's 2019 Annual General Meeting of Shareholders, which covered key corporate governance matters and shareholder decisions.
Shareholders overwhelmingly elected all twelve nominated directors. With the exception of one director who received approximately 87.8% of the votes cast, all other directors received over 95% of the votes cast, demonstrating strong shareholder confidence in the current board.
No, the advisory vote on named executive officer compensation was approved by a significant majority of shareholders, with over 94.7% voting in favor. This indicates general shareholder satisfaction with the company's compensation policies.
Shareholders strongly approved the renewal of the Board's authority to issue shares (98.9%) and to opt out of pre-emption rights (99.3%). Additionally, authorization for overseas market purchases of Medtronic ordinary shares was also approved with high support (99.3%).